Latest Healthcare News

Vitrafy Life Sciences has teamed up with Vitalant Innovation Center to tackle the impending gap in red blood cell cryopreservation technology in the US, aiming to replace soon-to-be-discontinued legacy methods and potentially expand into other blood products.

Imagion Biosystems has secured FDA clearance to proceed with its Phase 1b/2 trial of the MagSense® HER2 Imaging Agent, targeting improved detection of HER2+ breast cancer. Patient recruitment is expected to start in Q3 2026, marking a crucial step toward commercialisation.

Stakk Ltd has secured a significant U.S. healthcare technology contract, pushing its annualised revenue run rate to approximately A$26 million. The deal highlights accelerating adoption of its AI-native Digital Trust platform across regulated industries.

Green Cross Health plans to sell its Medical division, The Doctors, for NZ$270 million to Tend Health, refocusing on its pharmacy business. Completion hinges on shareholder approval expected by July 2026.

Intelligent Monitoring Group (ASX:IMB) has finalized its A$37 million purchase of Wormald NZ and Red Wolf, expanding its New Zealand footprint and projecting a 20.9% accretion in earnings per share.

Optiscan and Mayo Clinic have completed all key engineering milestones in their two-year partnership to develop a digital endomicroscopic imaging system for robotic surgery, extending their agreement to support further clinical and commercial planning.

ReNerve has inked an exclusive three-year deal with Hong Kong’s Swedish Trading Company to distribute its nerve repair products across a vast and dynamic healthcare region.

Little Green Pharma (ASX:LGP) has completed its merger with Cannatrek, creating a dominant player in Australia and Europe’s medicinal cannabis market with a majority stake held by former Cannatrek shareholders.

4DMedical has leapfrogged into the European lung health market by acquiring Austrian AI imaging firm contextflow, gaining immediate commercial presence and a CE-marked lung cancer screening solution.

Memphasys has inked its first exclusive commercialization agreement in South-East Asia with TMSC Vietnam, targeting the fast-growing Vietnamese IVF sector with its Felix™ sperm separation system. The two-year contract, valued at A$530,000, hinges on regulatory approval expected by August 2026.

Austco Healthcare expects FY26 revenue between A$90 million and A$95 million, driven by strong sales and a significant US rollout. Net profit after tax is forecast to jump over 50%, supported by operational growth and a one-off benefit.

ParagonCare anticipates recovering up to 32.5% of its exposure to the insolvent Infinity Retail Pharmacy Group, while maintaining a steady FY26 earnings outlook amid cost pressures.